MRgFUS FOR PARKINSON'S:
FOCUSED ULTRASOUND WITHOUT SURGERY
MRgFUS uses hundreds of precisely focused ultrasound beams to treat medication-resistant tremor and other disabling motor symptoms in Parkinson's disease โ no incision, no implant, no general anaesthesia. A complete guide for patients and families considering this option.
analyticsAt a Glance
- check_circleMRgFUS converges hundreds of ultrasound beams through the intact skull at a single brain target โ generating enough heat to create a precise lesion that interrupts abnormal tremor circuits.
- check_circleFDA-approved for medication-refractory tremor-dominant Parkinson's disease. Patients often see tremor improvement during the procedure itself โ results visible in real time.
- check_circleNo incision, no craniotomy, no implanted device, no general anaesthesia โ patients typically return home the same day or after brief observation.
- check_circleAvailable internationally including India and selected Asian centres at significantly lower cost than in the US โ CancerFax coordinates eligibility assessment and access.
What Is MRgFUS and How Does It Work?
MRgFUS stands for magnetic resonance-guided focused ultrasound. It combines real-time MRI imaging with focused ultrasound energy to treat deep brain targets without making a surgical incision. Hundreds of ultrasound beams pass through the scalp and skull individually โ each carrying minimal energy โ and converge at a precisely selected target. At the convergence point, the combined energy generates enough heat to create a small, permanent lesion that interrupts the abnormal electrical circuit causing tremor or other symptoms.
โImagine directing hundreds of individual sound beams through the scalp and skull to meet at one point inside the brain. Each beam is harmless alone โ but where they all meet, they deliver a precise, controlled treatment. No cut. No implant. No general anaesthesia.โ
What MRgFUS Does Not Require
No surgical incision or craniotomy. No implanted electrodes, wires, or battery device. No general anaesthesia. No weeks of recovery. Patients are awake throughout the procedure and typically return home the same day or after brief observation.
The ExAblate Neuro System
The most widely used MRgFUS system for Parkinson's disease is the ExAblate Neuro system developed by InSightec. It has received FDA approval and regulatory clearance in multiple countries for medication-refractory tremor-dominant Parkinson's disease.
Real-Time MRI Guidance
MRI imaging runs continuously throughout the procedure โ allowing the treating team to see exactly where the ultrasound energy is being delivered, monitor the developing lesion in real time, and verify that the treatment is precisely targeted before finalising each step.
What MRgFUS Does Not Do
MRgFUS does not restore dopamine, cure Parkinson's disease, or reverse disease progression. It interrupts a specific abnormal brain circuit to relieve a specific disabling symptom โ most effectively medication-resistant tremor. Non-motor symptoms, bilateral symptoms, and advanced disease are not effectively addressed.
Brain Targets: What Can Be Treated and Why
Different brain targets are used depending on the patient's primary symptom. Target selection is a specialist decision requiring a movement disorders neurologist and functional neurosurgeon.
VIM Nucleus (Thalamotomy) โ For Tremor-Dominant Parkinson's
The ventral intermediate nucleus of the thalamus is a relay station for movement signals. Lesioning the VIM is the most established and predictable MRgFUS application. Patients typically notice improvement in hand tremor during the procedure, with better control of eating, writing, drinking, and self-care. This is the FDA-approved indication.
Globus Pallidus Internus (GPi) โ For Dyskinesia and Motor Complications
GPi-targeted lesioning may reduce medication-induced dyskinesia (involuntary movements), improve rigidity, address motor fluctuations, and enhance overall motor scores. These approaches are evolving and require experienced centres with specific GPi expertise.
Subthalamic Nucleus (STN) โ Emerging
Newer approaches targeting the subthalamic nucleus or tract-level lesioning are being explored in clinical research for patients with broader motor dysfunction beyond tremor alone. These require careful patient selection and expert evaluation at specialist research centres.
Who May Benefit โ and Who Is Not Suitable
MRgFUS is not appropriate for all Parkinson's patients. Understanding who is and is not a good candidate is the most important step.
Strong Candidates
- Severe medication-resistant tremorTremor that significantly impacts eating, writing, drinking, or self-care despite optimised medication.
- Tremor-dominant Parkinson's diseaseTremor is the primary disabling feature โ not rigidity, gait, or non-motor symptoms.
- Mainly one-sided (unilateral) symptomsUnilateral tremor benefits most from a unilateral lesion.
- Medical reasons excluding DBSPatients who cannot or prefer not to have implanted hardware.
- Intact cognition and realistic expectationsAbility to cooperate during awake procedure and understand that MRgFUS relieves one symptom, not the whole disease.
Not Suitable
- Significant cognitive impairment or dementiaCannot safely consent or cooperate during the awake procedure.
- Bilateral or widespread motor symptomsA unilateral lesion will not adequately address bilateral disease.
- MRI-incompatible implantsPacemakers, certain metallic implants, or devices incompatible with continuous MRI.
- Skull anatomy limiting ultrasound transmissionDense or irregular skull bone may block adequate ultrasound delivery.
- Primarily non-motor symptomsMemory, mood, sleep, constipation, and autonomic symptoms are not addressed by MRgFUS.
The MRgFUS Treatment Procedure: Step by Step
MRgFUS is performed as a day procedure. Patients are awake throughout.
- 1
Head Frame Fitting and Scalp Preparation
The head is fitted with a stereotactic frame to keep it precisely positioned. The scalp is shaved to improve ultrasound transmission and a transducer helmet is fitted.
- 2
MRI Scanning and Target Planning
Detailed MRI scans define the precise brain target. The treatment team calculates the exact coordinates and confirms the plan before any ultrasound energy is delivered.
- 3
Low-Energy Test Sonications
Small amounts of ultrasound energy are delivered at increasing levels while the patient reports sensations and is assessed for tremor response. This allows real-time confirmation that the right target is being treated.
- 4
Therapeutic Sonication
Once target confirmation is complete, therapeutic energy is delivered to create the permanent lesion. Tremor improvement is typically visible immediately and assessed in real time by the treating team.
- 5
Recovery and Discharge
Post-procedure observation for several hours. Most patients are discharged the same day or after one overnight stay. Follow-up assessment scheduled at 1 week, 1 month, and 3 months.
MRgFUS vs Deep Brain Stimulation (DBS): Key Differences
Both MRgFUS and DBS are effective for carefully selected Parkinson's patients. The choice depends on symptom pattern, preference, and clinical circumstances.
MRgFUS Advantages
- No incision, no implant, no general anaesthesiaParticularly relevant for patients who cannot safely undergo surgery or who strongly prefer avoiding hardware.
- Same-day procedure โ rapid recoveryPatients typically go home the same day with no wound healing or device management.
- No hardware to maintain or replaceDBS batteries require replacement every 3-5 years; MRgFUS has no ongoing hardware component.
- Results visible during the procedureTremor improvement can be seen in real time โ immediate feedback on treatment effectiveness.
DBS Advantages
- Adjustable and reversibleDBS stimulation can be tuned, adjusted, or turned off as disease evolves. MRgFUS creates a permanent lesion.
- Bilateral treatment possibleDBS can treat both sides of the brain โ MRgFUS bilateral treatment carries higher risk of side effects.
- Broader symptom coverageDBS can address tremor, rigidity, bradykinesia, and motor fluctuations more comprehensively.
- Longer evidence baseDBS has decades of clinical outcome data across a broader patient population.
Key Evidence and Results
- ~75%Patients Reporting Meaningful Tremor ReductionAcross published trials for VIM thalamotomy in tremor-dominant Parkinson's disease.
- Same dayTypical Discharge After ProcedureMost patients return home the same day โ no hospitalisation required at most centres.
- PermanentNature of the LesionUnlike DBS, MRgFUS creates a permanent brain lesion โ the treatment cannot be reversed. This must be understood before proceeding.
- 1-3 hoursTypical Procedure DurationFrom helmet fitting to final sonication and recovery โ most procedures are completed within this window.
How CancerFax Helps You Access MRgFUS Internationally
MRgFUS for Parkinson's is available at specialist neurology centres internationally. CancerFax coordinates access for patients from outside the treating country.
- 1
Clinical Record Review
We review your neurology records, Parkinson's diagnosis history, current medications and response, tremor severity, and any prior brain imaging โ to assess whether MRgFUS evaluation is appropriate.
- 2
Centre Identification
We identify specialist neurology and functional neurosurgery centres with MRgFUS (ExAblate Neuro) capability and experience in Parkinson's disease applications.
- 3
Pre-Travel Eligibility Assessment
Reports submitted to the relevant movement disorders and neurosurgery team for specialist review before any travel decision. Skull CT for ultrasound transmission assessment may be required.
- 4
Full International Coordination
Documentation, visa, travel, hospital communication, interpretation, and post-procedure coordination with your home neurology team.
Frequently Asked Questions
About MRgFUS for Parkinson's Disease
Is MRgFUS a cure for Parkinson's disease?
No. MRgFUS does not cure Parkinson's disease, restore lost dopamine, or slow disease progression. It interrupts a specific abnormal brain circuit to relieve a specific disabling symptom โ most effectively medication-resistant tremor. The underlying disease continues to progress, and non-motor symptoms, bilateral motor symptoms, and other aspects of Parkinson's are not addressed by MRgFUS.
How long do the effects of MRgFUS last?
The lesion created by MRgFUS is permanent. Published follow-up data shows that meaningful tremor reduction is maintained in the majority of responding patients at 1-2 year follow-up. As Parkinson's disease continues to progress over time, new or worsening symptoms may develop โ but the specific symptom treated by MRgFUS should remain improved.
Can MRgFUS be repeated or performed on both sides?
Bilateral MRgFUS carries a significantly higher risk of permanent side effects โ particularly speech and swallowing difficulties โ and is generally not recommended. MRgFUS is typically a one-time, one-sided procedure. If tremor later develops prominently on the other side, alternative options including DBS may be considered. Repeating MRgFUS on the same side is generally not performed.
What are the side effects of MRgFUS?
Common temporary side effects during and after the procedure include dizziness, nausea, and headache. Permanent side effects include numbness or tingling in the treated hand or face (common, usually mild), and less commonly, imbalance or gait difficulty. Serious permanent deficits are uncommon with VIM thalamotomy but increase with bilateral procedures or off-target lesioning. All risks must be discussed individually with the treating team before the procedure.
How does CancerFax help patients access MRgFUS internationally?
CancerFax reviews neurology records, tremor severity, medication history, and imaging to assess whether MRgFUS is clinically appropriate. We identify specialist centres with confirmed MRgFUS capability for Parkinson's disease, submit records for pre-travel eligibility assessment, and coordinate all practical arrangements including documentation, translation, travel, hospital communication, and post-procedure follow-up with the home neurology team.
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination โ travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
Is MRgFUS the Right Option for Your Parkinson's Tremor?
Share your neurology records and tremor history โ our clinical team will assess whether MRgFUS evaluation is appropriate and identify specialist centres with the right expertise for your specific situation.
This information is for patient education and navigation only. All treatment decisions must be made in consultation with a qualified movement disorders neurologist and functional neurosurgeon.